Cerity Partners
HRTX icon

Cerity Partners’s Heron Therapeutics HRTX Stock Holding History

Cerity Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8K Buy
17,243
+180
+1% +$209 ﹤0.01% 3196
2025
Q4 		$22.2K Sell
17,063
-34,649
-67% -$42.8K ﹤0.01% 2841
2025
Q3 		$65.2K Buy
+51,712
New +$82K ﹤0.01% 2668
2024
Q4 		– Sell
-10,348
Closed -$20.6K – 2505
2024
Q3 		$20.6K Buy
+10,348
New +$24.7K ﹤0.01% 2512
2020
Q4 		– Sell
-35,600
Closed -$528K – 649
2020
Q3 		$528K Sell
35,600
-2,438
-6% -$38K 0.02% 315
2020
Q2 		$560K Buy
38,038
+2,438
+7% +$40.1K 0.03% 267
2020
Q1 		$418K Sell
35,600
-850
-2% -$16K 0.03% 303
2019
Q4 		$857K Buy
36,450
+1,370
+4% +$30.3K 0.04% 259
2019
Q3 		$649K Buy
35,080
+10,080
+40% +$186K 0.04% 284
2019
Q2 		$465K Sell
25,000
-90
-0.4% -$1.8K 0.03% 330
2019
Q1 		$613K Buy
+25,090
New +$657K 0.04% 301

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cerity Partners's HRTX Position: Q1 2026 in Review

Cerity Partners increased its Heron Therapeutics (HRTX) stake by 1.1% in Q1 2026, buying an estimated $209 and bringing the position to 17,243 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3196.

Cerity Partners first reported a position in HRTX in Q1 2019 and has held it in 11 quarters since. The position peaked at $857K in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Cerity Partners held 17,243 shares of Heron Therapeutics worth $13.8K as of Q1 2026.
  • Cerity Partners bought 180 Heron Therapeutics shares in Q1 2026, an estimated $209.
  • Heron Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3196 holding.
  • Cerity Partners first reported a position in Heron Therapeutics in Q1 2019 and has held it in 11 quarters since.
  • Cerity Partners's Heron Therapeutics position peaked at $857K in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.